Abstract
Ezetimibe is a selective acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor used in hypercholesterolemia. Synthesis of ezetimibe requires enantiopure 3-[5-(4-fluorophenyl)-5(S)-hydroxypentanoyl]-4(S)-4-phenyl-1,3-oxazolidin-2-one (FOP alcohol) as a crucial intermediate which is produced by reduction of the corresponding prochiral ketone (FOP dione). A new biocatalyst from acclimatized soil was screened for bioreduction of the above prochiral ketone. The microorganism was identified by 16S mRNA sequencing, as Burkholderia cenocepacia. Various physicochemical conditions were optimized to increase cellmass and enzyme activity. The overall increase in cellmass concentration and enzyme activity was 2.06 and 1.85-fold, respectively. Various reaction conditions, for example pH, temperature, agitation, and cellmass concentration, were optimized for maximum product yield (chiral alcohol) with excellent enantioselectivity. Best reduction was achieved in phosphate buffer (50 mM, pH 8.0) at 40°C (200 rpm) and the yield of enantiopure alcohol from the corresponding prochiral ketone was 54%. This biocatalyst was also used for the reduction of various other prochiral ketones.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
May SW (1999) Applications of oxidoreductases. Curr Opin Biotechnol 10:370–375
Caner H, Groner E, Levy L (2004) Trends in the development of chiral drugs. Drug Discov Today 9:105–110
Patel RN (2008) Synthesis of chiral pharmaceutical intermediates by biocatalysis. Coord Chem Rev 252:659–701
Neal RC, Jones PH (2003) Lipid-lowering: can ezetimibe help close the treatment gap. Clin J Med 70:777–783
Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M (2006) Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med Hypotheses 66:844–846
Moutasim HA, Nabil EC, Ehab SS (2004) The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia. Lipids Health Dis 3:22–28
Schering Corporation (2001) Process for the synthesis of azetidinones. US Patent 6,207,822
Schering Corporation (2000) Process for the synthesis of azetidinones. WO 00/34240
Fu X, Timothy LM, Thiruvengadam TK, Tann CH, Dan S (2003) Process for preparing ezetimibe intermediate by an acid enhanced chemo- and enantio-selective CBS catalyzed ketone reduction. Tetrahedron Lett 44:801–804
Bertrand B, Durassier S, Frein S, Burgos A (2007) Process for preparing ezetimibe intermediate by enantioselective CBS catalyzed ketone reduction with BH3–DEA prepared in situ. Tetrahedron Lett 48:2123–2125
Schering Corporation (1997) Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof. US Patent 5618707
Acknowledgments
AS and AB are thankful to Department of Biotechnology, Ministry of Science and Technology, Government of India, for providing fellowship and financial assistance for the project. This is NIPER communication number 443.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh, A., Basit, A. & Banerjee, U.C. Burkholderia cenocepacia: a new biocatalyst for efficient bioreduction of ezetimibe intermediate. J Ind Microbiol Biotechnol 36, 1369–1374 (2009). https://doi.org/10.1007/s10295-009-0622-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10295-009-0622-z